Treatments reported in three or more studies (excluding IRT and antibiotics)a
| Treatment type | Median percentage of patients (range) | No. of publications |
|---|---|---|
| Steroids | 56.4 (32.9–85.7) | 9 |
| Rituximab | 12.2 (5.5–34.8) | 7 |
| Mycophenolate | 7.4 (1.8–13.2) | 6 |
| Azathioprine | 7.0 (3.6–28.6) | 8 |
| Antimalarials | 4.4 (2.6–7.3) | 4 |
| TNF-α inhibitors | 3.7 (1.5–9.0) | 5 |
| Methotrexate | 3.6 (0.8–15.4) | 5 |
| Tacrolimus | 3.0 (2.6–3.0) | 3 |
| Cyclophosphamide | 2.6 (0.4–10.9) | 3 |
| Abatacept | 2.4 (0.4–3.0) | 4 |
| Sirolimus | 2.0 (0.8–7.5) | 4 |
| Cyclosporine | 1.7 (0.8–2.2) | 4 |
| Treatment type | Median percentage of patients (range) | No. of publications |
|---|---|---|
| Steroids | 56.4 (32.9–85.7) | 9 |
| Rituximab | 12.2 (5.5–34.8) | 7 |
| Mycophenolate | 7.4 (1.8–13.2) | 6 |
| Azathioprine | 7.0 (3.6–28.6) | 8 |
| Antimalarials | 4.4 (2.6–7.3) | 4 |
| TNF-α inhibitors | 3.7 (1.5–9.0) | 5 |
| Methotrexate | 3.6 (0.8–15.4) | 5 |
| Tacrolimus | 3.0 (2.6–3.0) | 3 |
| Cyclophosphamide | 2.6 (0.4–10.9) | 3 |
| Abatacept | 2.4 (0.4–3.0) | 4 |
| Sirolimus | 2.0 (0.8–7.5) | 4 |
| Cyclosporine | 1.7 (0.8–2.2) | 4 |
TNF-α, tumor necrosis factor alpha.
Six case studies reporting monotherapies were excluded, as all patients were administered the same treatment.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.